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ABSTRACT 
Dysfunctions of Wnt, Hedgehog and Notch pathways are evident in multiple tumor types and malignancies. A number of studies 
have suggested that dysregulation of Wnt/β-catenin signaling occurs in human breast cancer. Specifically, inhibition of Wnt/ β-
catenin pathway is implicated in arresting of cancer stem cells (CSCs), a small subset of cancer cells capable of self-renewal and 
differentiation into heterogeneous tumor cells. Here, we investigated tumor initiating property of breast cancer stem cell in-vitro with 
XAV-939 an inhibitor of Wnt/β-catenin signaling pathway. Targeting Wnt/β-catenin signaling with this inhibitor represents a 
promising strategy to suppress metastasis. 
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INTRODUCTION 
Amongst women, breast cancer is the most common 
cancer in both developed and developing countries of 
the globe, and the second reason of mortality in 
developed countries after lung cancer 
1
. Breast cancer 
death rate has been reducing in most high-income 
regions of North America and Europe due to screening, 
early detection and admission to adjuvant treatments 
2, 3
. 
Screening programs are assessed to have declined breast 
cancer mortality in 20% in the invited population 
4, 5
. 
Moreover, breast carcinoma is one of the fields in cancer 
that has perceived some major advances in the 
understanding of the fundamental biology with the 
molecular characterization into discrete entities, as well 
as changes in terms of treatment and prognosis in the 
last fifteen years, as demonstrated by the use of 
trastuzumab for the adjuvant treatment of women with 
HER-2 overexpressing early-stage and advanced breast 
cancer 
6
. Whereas these developments have improved 
patient outcomes, some disease continue to be resistant 
to current treatments are still poorly understood. Also, 
both incidence and mortality from breast cancer are 
increasing in moderate-income countries of the world 
where significant challenges remain. 
The conventional treatments like chemotherapy and 
radiotherapy fails to cure the disease most of the time 
and this may be due to the presence of cancer stem cells 
(CSCs). Cancer metastasis, resistance to therapies and 
disease recurrence are significant hurdles to successful 
treatment of breast cancer. Cancer stem cells (CSCs) are 
a small subset of cancer cells with the capability of self-
renewal and differentiation into heterogeneous tumor 
cells, and they have been believed to be responsible for 
tumor initiation, growth, and recurrence 
7
. First, CSCs 
possess a high tumor-initiating capacity, which is an 
essential characteristic that enables the formation of new 
tumours 
8
. Moreover, CSCs also associated an 
epithelial-mesenchymal transition (EMT) marker 
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which helps the tumor cells to migrate into other 
organs and tissues 
9
. 
Wnt signaling is essential for normal breast stem cell 
function and mammary gland development. Numbers 
of studies have shown that aberrant Wnt signaling in 
breast cancer stem cells is a crucial event in breast 
tumorigenesis 
10
. Abnormal activation of Wnt signaling 
has been implicated in the regulation of a plethora of 
CSC types including colorectal cancer, breast cancer, 
hematologic cancer, skin cancer, liver cancer and lung 
cancer 
11, 12, 13, 14, 15, 16
. Recent study also demonstrated 
that Wnt/β-catenin signaling activity is higher in 
breast CSCs than the bulk tumor population 
17
. 
Markers like CD44
+
/CD24
-
 have been proposed to 
exhibit enhanced tumorigenic and metastatic 
properties in tumor xenograft models 
18,19
.  
Here, we investigated the effects of inhibiting Wnt/β-
catenin signaling on breast cancer stem cell to link its 
tumor initiating ability through 3D mammosphere 
formation. Targeting Wnt/β-catenin signaling with this 
XAV-939 inhibitor represents a promising strategy to 
suppress metastasis. 
MATERIALS & METHODS 
Cell lines and Culture Conditions 
TMD-231 breast carcinoma cell line was obtained 
directly from the ATCC (Manassas, VA, USA), and 
grown in DMEM (Thermo Fisher Scientific, Carlsbad, 
CA) supplemented with 10% fetal bovine serum (FBS, 
Sigma, St. Louis, MO) at 37°C in a 5% humidified 
CO2incubator. Characterization of cell line was done 
according to their surface expression phenotype.TMD-
231 cell lines were grown for 48 hours with 80% 
confluency. After that the same cell lines were treated 
with XAV-939 inhibitor for 72 hours. These cells were 
used to form 3D mammosphere along with 
controls.XAV-939 Inhibitor was purchased from 
selleckchem (USA).  
3D Mammosphere formation 
Single cell suspensions were plated in 6-well tissue 
culture plates covered with poly-2-hydroxyethyl-
methacrylate (Sigma, St. Louis, MO) to prevent cell 
attachment, at a density of 1,000 cells/ml in serum-free 
DMEM supplemented with 1% L-glutamine, 1% 
penicillin/streptomycin, 30% F12 (Sigma), 2% B27 
(Thermo Fisher Scientific, Carlsbad, CA), 20 ng/ml EGF 
(Sigma, St. Louis, MO) and 20 ng/ml FGFb (Thermo 
Fisher Scientific, Carlsbad, CA). The medium was made 
semi-solid by the addition of 0.5% Methylcellulose 
(R&D Systems, Minneapolis, MN) to prevent cell 
aggregation. After 7 days in culture, mammospheres 
were collected by gentle centrifugation (200 x g) and 
dissociated enzymatically (5 min in 1:1 trypsin/DMEM 
solution at 37°C) and mechanically by passing through a 
25G needle (6 strokes). Single cells were re-plated at a 
density of 1,000 cells/ml for subsequent passages. 
Viability Assay 
TMD-231 cells were grown in a 96-well tissue culture 
plate with drugs and appropriate controls. Subsequently 
they were incubated with the WST-1 reagent (Dojindo 
Inc, Japan) for 4 hours. After this incubation period, the 
formazan dye formed was quantitated with a multi-well 
spectrophotometer (ELISA reader). The measured 
absorbance directly correlates to the number of viable 
cells. 
Flow cytometry 
PE-conjugated CD44, FITC-conjugated CD24 
monoclonal antibody was purchased from BD 
Bioscience.  After 3 days of drug treatment the TMD-
231 cells were dissociated with 0.25 % trypsin-EDTA (1 
mM) (Invitrogen) for 3 min and washed with Calcium 
and magnesium free dulbecco phosphate buffered saline 
solution by spinning at 400g for 7 minutes. Then these 
cells were diluted in 100 µl FACS buffer (PBS 
containing 1 % fetal calf serum) and then incubated for 1 
hr at 4 °C in FACS buffer with the corresponding mAb: 
anti-CD44-PE, CD24-FITC. Flow cytometry analysis 
was performed with a BD FACSCanto II flow cytometer 
(BD Biosciences). 
RESULTS 
Viability of TMD-231-Cell lines in the presence of 
XAV-939 inhibitor 
 
Figure 1: The graph representing the viability of 
control and XAV-939 treated TMD-231 cell lines at 
day 3 culture. The absorbance readings were taken at 
450 nm.  
After 3 days of XAV-939 treatment, TMD-231 cell 
lines were measured for the viability by WST-1 
method. We observed very minimal or negligible 
difference between control and XAV-939 treated cell 
lines, and the same was observed in the morphological 
images under inverted microscope (data not shown 
here). This result indicates, even though XAV-939 
play a major role in suppressing wnt β-catenin 
signaling pathway it did not affect the viability of the 
cells.
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Expression profiles of breast CSC markers 
Figure 2: Flow cytometry analysis representing the 
expression of breast cancer stem cell markers 
CD44+/CD24-. A] In control, the expression of 
CD44/CD24 was 6.05%. B] In XAV-939 treated cells 
the expression of CD44 was 1.04%. 
We examined the expression profiles of breast cancer 
stem cell markers in TMD-231 cells with or without 
Wnt1 inhibitor i.e. XAV-939. We noticed significant 
decrease of breast cancer stem cell markers 
CD44
+
/CD24
− 
when compared to the control. However, 
in control the expression pattern of breast cancer stem 
cell was unchanged. These findings were very evident 
that wnt/β-catenin signaling plays a vital role in cancer 
stem cell.  So, arresting or blocking the wnt-βcatenin 
signaling can suppress the breast cancer stem cell which 
involves in multiple roles like tumorigenesis, 
chemoresistance and tumors relapse. 
Suppression of metastasis 
 
 
 
Figure 3: 3D Mammosphere formation assay. The first 
image is pre XAV-939 treated cells, no mammosphere 
was observed even after 9 days of spheroid culture. 
Second image, TMD-231 cells forming 3D 
mammosphere at day 5. Third image, TMD-231 cells 
forming mammosphere at day 7.   
To further confirm the effects of Wnt/β-catenin 
signaling on tumor cells we formed 3D 
mammospehres. We used XAV-939 treated cells along 
with normal TMD-231 cells as a control for spheroid 
formation assay. Interestingly the data was very much 
correlated with the flow cytometry analysis. The 
spheroids were started forming at day 3 itself (data not 
shown here) in control whereas in XAV-939 treated 
cells we couldn't find any mammosphere even after 9
th
 
day of culture. These results suggest that wnt-β 
catenin signaling is very much required for tumor 
initiating capability and metastasis which are 
conferred by CSCs. 
 
DISCUSSION 
Like in any other cancers, breast cancer also fails to 
respond to their current chemotherapies. The 
resistance and recurrence are contributed by cancer 
stem cells. Hence, the identification of CSCs in breast 
cancer represents an important milestone in the 
understanding of chemo-drug resistance and cancer 
recurrence. Targeting and eradication of these cells 
represents a potential strategy to improve the clinical 
outcomes. 
Recent understandings of the biological characteristics 
of breast cancer stem cells have facilitated the 
identification of mechanisms underlying the 
development of malignant breast cancer. One such 
mechanism is dysregulation of Wnt/β-catenin 
signaling occurs in breast cancer 
20
. In this context, 
abnormal Wnt/β-catenin signaling activity may be an 
important clinical and pathologic feature of breast 
cancer and a predictor of poor overall survival 
21
. 
XAV-939 specifically inhibits tankyrase PARP activity. 
CD44- 
FITC 
 
CD24-PE 
CD44- 
FITC 
CD24-PE 
Control XAV939 treated TMD-231 cells 
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XAV-939 deregulates the Wnt/b-catenin pathway which 
has been implicated in many cancers including breast. 
Moreover, tankyrase 1 (TNKS1) inhibition may in part 
blocked Wnt/β-catenin signaling and reduced the 
expression of anti-apoptosis protein. Also, inhibition of 
TNKS1 reduced colony formation in vitro 
22
. 
In this study, we treated TMD-231 cell lines with 
XAV-939, an inhibitor of Wnt/β-catenin signaling 
pathway that resulted in 1) decreased levels of the 
stem cell markers CD44+/CD24
-
2) Reduced 3D 
mammosphere formation. However, there were not 
much difference in their cell viability. 
CONCLUSION 
Tumor initiating ability is one of the important 
characteristics of cancer stem cell. In breast cancer 
presence of these cancer stem cells notably the 
CD44
+
/CD24
−
 subpopulation is enriched under 
suspension sphere culture conditions. Abolishing the 
3D mammosphere forming capacity in the TMD-231 
cancer cell line is a direct indication of suppression of 
metastasis with a blockade in Wnt/β-catenin signaling 
pathway.
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